LIRAGLUTIDE Drug Patent Profile

When do Liraglutide patents expire, and when can generic versions of Liraglutide launch?

Liraglutide is a drug marketed by Hikma, Lupin Ltd, Nanjing King Friend, Orbicular, and Teva Pharms. and is included in five NDAs.

The generic ingredient in LIRAGLUTIDE is liraglutide. There are seven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the liraglutide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Liraglutide

A generic version of LIRAGLUTIDE was approved as liraglutide by HIKMA on December 23^rd, 2024.

Summary for LIRAGLUTIDE

US Patents:	0
Applicants:	5
NDAs:	5
Finished Product Suppliers / Packagers:	8
Clinical Trials:	455
Patent Applications:	3,456
Drug Prices:	Drug price information for LIRAGLUTIDE
What excipients (inactive ingredients) are in LIRAGLUTIDE?	LIRAGLUTIDE excipients list
DailyMed Link:	LIRAGLUTIDE at DailyMed

See drug prices for LIRAGLUTIDE

Recent Clinical Trials for LIRAGLUTIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Fourth Affiliated Hospital of Zhejiang University School of Medicine	PHASE4
Novo Nordisk A/S	PHASE1
Evira AB	NA

See all LIRAGLUTIDE clinical trials

Pharmacology for LIRAGLUTIDE

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Anatomical Therapeutic Chemical (ATC) Classes for LIRAGLUTIDE

A10BJ	Glucagon-like peptide-1 (GLP-1) analogues
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

Paragraph IV (Patent) Challenges for LIRAGLUTIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
SAXENDA	Injection	liraglutide	18 mg/3 mL prefilled syringe	206321	1	2021-08-16
VICTOZA	Injection	liraglutide	18 mg/3 mL prefilled syringe	022341	1	2016-12-12

US Patents and Regulatory Information for LIRAGLUTIDE

LIRAGLUTIDE is protected by zero US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hikma	LIRAGLUTIDE	liraglutide	SOLUTION;SUBCUTANEOUS	215503-001	Dec 23, 2024	AP1	RX	No	No
Orbicular	LIRAGLUTIDE	liraglutide	SOLUTION;SUBCUTANEOUS	217590-001	Jan 14, 2026	AP1	RX	No	No
Lupin Ltd	LIRAGLUTIDE	liraglutide	SOLUTION;SUBCUTANEOUS	215421-001	Jul 22, 2025	AP1	RX	No	No
Nanjing King Friend	LIRAGLUTIDE	liraglutide	SOLUTION;SUBCUTANEOUS	218115-001	Apr 2, 2025	AP1	RX	No	No
Teva Pharms	LIRAGLUTIDE	liraglutide	SOLUTION;SUBCUTANEOUS	214568-001	Aug 27, 2025	AP2	RX	No	No

Market Dynamics and Financial Trajectory for Liraglutide

Last updated: March 12, 2026

What is the Current Market Position of Liraglutide?

Liraglutide is a GLP-1 receptor agonist approved for type 2 diabetes management and obesity treatment. It is marketed under brands including Victoza (diabetes) and Saxenda (weight management). Developed by Novo Nordisk, liraglutide has gained market approval in over 80 countries, with global sales surpassing USD 5.5 billion in 2022 [1].

What Are the Key Market Drivers?

Increasing Prevalence of Type 2 Diabetes: The International Diabetes Federation estimates 537 million adults worldwide have diabetes, projected to reach 643 million by 2030 [2]. Obesity rates mirror this trend, fueling demand.

Efficacy in Glycemic and Weight Control: Liraglutide demonstrates superior HbA1c reduction and weight loss compared to other treatments. Its once-daily dosing improves patient compliance.

Regulatory Approvals and Label Expansion: In 2022, the FDA approved higher doses of Saxenda for obesity, extending liraglutide's market potential. The European Medicines Agency also approved expanded indications.

Development of Fixed-Dose Combinations: Combinations with other antidiabetics, such as insulin, enhance therapeutic options, expanding liraglutide’s application scope.

Shift Toward Patient-Centric Therapies: Preference for injectable therapies with proven efficacy shapes market adoption.

How Do Competition and Patent Status Affect the Market?

Competitive Landscape: Semaglutide (Wegovy, Ozempic) and dulaglutide (Trulicity) are primary competitors. Semaglutide's weekly dosing and higher efficacy in weight loss have challenged liraglutide's market share [3].

Patent Expiry and Biosimilar Development: Novo Nordisk’s patent for Victoza expires in 2027. Patent challenges and biosimilar entry could lower prices and erode market momentum.

What are the Financial Trajectories and Growth Projections?

Revenue Trends: Post-2016 launch of Saxenda, liraglutide revenues grown at an average annual rate of 15%. Sales peaked at USD 5.5 billion in 2022, with projections to reach USD 7 billion by 2025 if no significant market disruptions occur [4].

Market Penetration Strategies: Novo Nordisk invests in expanding access in emerging markets, where obesity and diabetes prevalence rise rapidly. Launch of new formulations, such as microgram-scale injections, aims to improve adherence.

Pricing and Reimbursement Trends: In high-income countries, reimbursement remains favorable, supporting premium pricing for liraglutide. In emerging markets, price adjustments are underway to penetrate broader populations.

Impact of Biosimilars: Entry anticipated post-2027 could reduce prices by 20–40%, pressuring revenue growth.

What Regulatory and Policy Factors Influence Market and Financial Outcomes?

Approval Timelines: Rapid approval processes in major markets accelerate revenue realization. Delays or rejections can limit growth.

Medication Guidelines: Inclusion in recent ADA/EASD guidelines as a preferred agent underpins sustained demand [5].

Reimbursement Policies: Reimbursement coverage is critical. Favorable policies directly influence patient access and sales.

Patent Litigation and Copyright Laws: Patent disputes and legal challenges can delay biosimilar entry, affecting revenue trajectories.

Conclusion

Liraglutide maintains a strong market position driven by rising diabetes and obesity prevalence, product efficacy, and regulatory support. Competition from semaglutide, impending patent expirations, and biosimilar development pose risks. Revenue growth remains robust but is susceptible to pricing pressures and policy changes. Tailored strategies focusing on emerging markets, formulation innovations, and leveraging guideline endorsements will be critical for sustaining long-term financial performance.

---

Key Takeaways

• Liraglutide's 2022 sales exceeded USD 5.5 billion; projected to reach USD 7 billion by 2025.
• Competition from semaglutide and upcoming biosimilars will challenge market share.
• Patent expiration in 2027 may lead to biosimilar entry, reducing prices and margins.
• Regulatory approvals and reimbursement policies significantly influence sales trajectories.
• Expanding indications and formulation improvements will support continued growth.

---

FAQs

1. How does liraglutide compare to semaglutide in terms of efficacy?
Semaglutide generally shows higher efficacy in weight loss and HbA1c reduction, especially with weekly dosing, which has led to increased market share.

2. What is the timeline for biosimilar entry?
Biosimilars are expected post-2027, following patent expiration. Market entry and pricing will depend on generic approval timelines.

3. Are there new formulations of liraglutide under development?
Yes, efforts include developing auto-injectors with simplified dosing and combination therapies to improve compliance.

4. How does reimbursement impact liraglutide sales?
Favorable reimbursement policies in high-income countries sustain premium pricing and access, supporting revenue growth.

5. What emerging markets hold significant potential for liraglutide?
India, China, and Southeast Asian nations are expanding markets due to rising diabetes and obesity rates, with tailored pricing strategies.

---

References

[1] Novo Nordisk. (2023). Annual report 2022. https://www.novonordisk.com/investors/annual-report.html

[2] International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th edition.

[3] European Society of Cardiology. (2022). GLP-1 receptor agonists in clinical practice: Semaglutide vs. Liraglutide.

[4] MarketWatch. (2023). Liraglutide market forecast and analysis.

[5] American Diabetes Association. (2022). Standards of Medical Care in Diabetes—2022.

---